Sarepta Therapeutics, Inc. (SRPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 800M 1.6B 2.4B FY14: 9.8M FY15: 1.3M FY16: 5.4M FY17: 154.6M FY18: 301M FY19: 380.8M FY20: 540.1M FY21: 701.9M FY22: 933M FY23: 1.2B FY24: 1.9B FY25: 2.2B FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 800M 1.6B 2.4B FY25: 2.2B FY25

Operating Income Annual

-750M -500M -250M 0 250M 500M 750M FY09: -15.5M FY10: -20.9M FY11: -35.9M FY12: -29.7M FY13: -90.3M FY14: -133.8M FY15: -220.2M FY16: -266.7M FY17: -171.6M FY18: -343.6M FY19: -705.6M FY20: -564.2M FY21: -459.7M FY22: -536.2M FY23: -267.8M FY24: 218.1M FY25: -699.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-750M -500M -250M 0 250M 500M 750M FY09: -25.2M FY10: -32.2M FY11: -2.3M FY12: -121.3M FY13: -112M FY14: -135.8M FY15: -220M FY16: -267.3M FY17: -50.7M FY18: -361.9M FY19: -715.1M FY20: -554.1M FY21: -418.8M FY22: -703.5M FY23: -536M FY24: 235.2M FY25: -713.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 9M 18M 27M FY25: 25.5M FY25

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY09: -8.8M FY10: -15.2M FY11: -23.7M FY12: -29.7M FY13: -64.7M FY14: -128.5M FY15: -149.5M FY16: -245.8M FY17: -232M FY18: -388.7M FY19: -456.5M FY20: 107.5M FY21: -443.2M FY22: -325.3M FY23: -501M FY24: -205.8M FY25: -205.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY09: -9.7M FY10: -16M FY11: -24.9M FY12: -29.8M FY13: -67.1M FY14: -154M FY15: -152.9M FY16: -251.2M FY17: -244M FY18: -449.8M FY19: -516.1M FY20: 25.3M FY21: -481.7M FY22: -356.2M FY23: -577.1M FY24: -342.7M FY25: -307.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 50M 100M 150M FY09: 93.1M FY10: 111.2M FY11: 129.6M FY12: 23.6M FY13: 33.9M FY14: 40M FY15: 42.3M FY16: 48.7M FY17: 58.8M FY18: 66.2M FY19: 73.6M FY20: 78M FY21: 81.3M FY22: 87.6M FY23: 92.4M FY24: 107.9M FY25: 100.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q1 '11: -1.72 Q2 '11: -1.51 Q3 '11: -1.62 Q4 '11: -0.16 Q1 '12: -0.31 Q2 '12: -0.02 Q3 '12: -2.01 Q4 '12: -4.31 Q1 '13: -5.50 Q2 '13: -6.45 Q3 '13: -5.52 Q2 '14: -3.07 Q3 '14: -2.54 Q4 '14: -3.39 Q1 '15: -4.13 Q2 '15: -4.29 Q3 '15: -4.83 Q4 '15: -5.19 Q1 '16: -5.01 Q2 '16: -5.35 Q3 '16: -5.28 Q4 '16: -5.46 Q1 '17: -2.65 Q2 '17: -2.45 Q3 '17: -2.05 Q4 '17: -0.80 Q1 '18: -2.85 Q2 '18: -3.37 Q3 '18: -3.74 Q4 '18: -5.42 Q1 '19: -5.94 Q2 '19: -8.01 Q3 '19: -8.56 Q4 '19: -9.67 Q1 '20: -8.83 Q2 '20: -7.02 Q3 '22: -8.22 Q4 '22: -8.03 Q1 '23: -12.69 Q2 '23: -10.31 Q3 '23: -7.83 Q4 '23: -5.80 Q1 '24: 0.43 Q2 '24: 0.77 Q3 '24: 1.57 Q4 '24: 2.28 Q1 '25: -2.69 Q2 '25: -0.87 Q3 '25: -3.01 Q4 '25: -8.44 Q1 '26: -0.96 Q2 '26: -2.90 Q3 '11 Q2 '13 Q3 '15 Q2 '17 Q1 '19 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.